Protocol Ledger

NCT04765384 · Phase II · COMPLETED

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

Interventional Phase II clinical trial protocol NCT04765384 sponsored by Johnson & Johnson / Janssen in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-27 Enrollment: 51 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04765384
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04765384
Protocol FieldVerified Registry Value
NCT IdentifierNCT04765384
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment51 participants (ACTUAL)
Registered Start Date2021-08-27
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI